Welcome to our dedicated page for TANDEM DIABETES CARE SEC filings (Ticker: TNDM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on TANDEM DIABETES CARE's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into TANDEM DIABETES CARE's regulatory disclosures and financial reporting.
TANDEM DIABETES CARE INC (TNDM) reported insider equity activity by EVP & Chief Financial Officer Leigh Vosseller on August 15, 2026. Two blocks of restricted stock units (RSUs) covering 1,496 and 2,624 underlying shares were converted into common stock, and related RSU entries were removed.
Vosseller acquired 1,496 and 2,624 shares of common stock through these RSU vestings at a conversion price of $0.00 per share. A total of 537 and 942 shares were then withheld by Tandem Diabetes Care at $22.72 per share to satisfy tax withholding obligations; footnotes state that no shares were sold. Following these transactions, 25,580 shares of common stock are reported as held indirectly in the Leigh A. Vosseller Trust, for which Vosseller serves as trustee.
For TANDEM DIABETES CARE INC (TNDM), President & CEO John F. Sheridan reported the vesting and settlement of restricted stock units on August 15, 2026. Two RSU grants covering 5,982 and 9,934 units, awarded under the company’s 2023 Long-Term Incentive Plan, were converted into an equal number of common shares at no exercise price. To cover associated tax withholding on these vestings, the issuer withheld 3,044 and 5,055 common shares at a reference value of $22.72 per share; according to the disclosure, these were not open-market sales but shares retained by the company for tax purposes.
TANDEM DIABETES CARE INC (TNDM) reported insider equity activity by executive officer Susan Morrison, EVP & Chief Admin. Officer. On 2026-08-15, 2,827 shares of common stock were acquired through the vesting and conversion of restricted stock units, while 809 shares were withheld by the issuer to satisfy tax withholding obligations at $22.72 per share. Footnotes state that no shares were sold in the market; the transactions reflect equity compensation vesting and related tax withholding rather than open-market trading.
TANDEM DIABETES CARE INC (TNDM) executive Jean-Claude Kyrillos reported the vesting of restricted stock units and related share movements. On 2026-08-15, 1,010 RSUs granted on May 30, 2025 under the 2023 Long-Term Incentive Plan were converted into 1,010 shares of common stock. Of these, 535 shares were withheld by the company at $22.72 per share to satisfy tax withholding requirements, with no shares sold in the market, leaving a net 475 shares issued. Following the RSU vesting event, Kyrillos holds 7,067 RSUs that will continue to vest in eight equal quarterly installments, subject to the plan’s terms.
TANDEM DIABETES CARE INC (TNDM) reported that EVP and Chief Strategy Officer Elizabeth Anne Gasser exercised 3,014 Restricted Stock Units into an equal number of shares of common stock on August 15, 2026. Of these, 1,618 shares of common stock were withheld at $22.72 per share to satisfy tax withholding requirements upon RSU vesting, and the company notes that no shares were sold in the market. Following these transactions, 33,109 shares of common stock are reported as held indirectly through The Gasser Family Trust, where she is a co-trustee.
TANDEM DIABETES CARE INC (TNDM) reported insider equity activity by EVP & Chief Technology Officer Rick Carpenter. On August 15, 2026, he exercised 2,507 Restricted Stock Units, receiving an equal number of common shares at $0.00 per share. Of these, 1,277 shares of common stock were withheld at $22.72 per share to satisfy tax withholding requirements upon RSU vesting, and the company states that no shares were sold. The RSUs were granted under Tandem’s 2023 Long-Term Incentive Plan and vest over time in quarterly installments.
TANDEM DIABETES CARE INC (TNDM) reported that EVP & Chief Legal Officer Shannon Marie Hansen had 3,014 Restricted Stock Units vest and convert into an equal number of common shares on 2026-08-15. Of these, 1,535 shares were withheld at $22.72 per share to cover tax obligations, with no open‑market sales. A separate indirect holding of 1,935 common shares is reported in the Shannon M. Hansen Trust.
Tandem Diabetes Care, Inc. (TNDM) received a notice under Rule 144 that Mark Novara intends to sell common stock through Morgan Stanley Smith Barney LLC. The filing lists a proposed sale of 131 shares of common stock on or about August 18, 2026 on NASDAQ.
The shares derive from restricted stock units, with the underlying securities noted as becoming available on August 15, 2026. The notice also reports prior 10b5-1 plan sales by Novara over the past three months.
Tandem Diabetes Care reported higher sales and a smaller loss for the quarter ended June 30, 2026. Sales rose to $254.6 million from $240.7 million a year earlier, with first-half 2026 sales of $501.8 million. Q2 gross profit increased to $144.8 million, while operating expenses declined to $158.6 million due to the absence of prior-year litigation and acquired in-process R&D charges. The Q2 operating loss narrowed to $13.8 million, and net loss to $21.2 million, or $0.31 per share, compared with a $52.4 million loss, or $0.78 per share, in Q2 2025. For the first half, net loss improved to $41.6 million from $183.0 million.
At June 30, 2026, cash and cash equivalents were $62.8 million and short-term investments $393.2 million, with total assets of $1.15 billion and stockholders’ equity of $130.4 million. Long-term convertible senior notes increased to $602.6 million after issuing $300.0 million of 0.00% notes due 2032 and entering related capped call transactions. Operating cash outflow was $23.6 million for the first half, while financing activities provided $276.3 million. Tandem expanded its equity method investment in CeQur SA by CHF 64.0 million ($81.4 million) and continues to hedge foreign currency exposure with forward contracts. Strategically, the company is shifting U.S. reimbursement toward a pay-as-you-go pharmacy model, submitted a 510(k) for Tandem Mobi tubeless capability, and is managing infusion set supply constraints expected to persist through 2026.
Tandem Diabetes Care, Inc. reported second quarter 2026 results with worldwide sales of $254.6 million, a 6% increase from $240.7 million, including U.S. sales of $179.3 million and international sales of $75.3 million. Pump shipments exceeded 33,000 units worldwide, with about 22,000 in the U.S. and 11,000 internationally.
Gross profit was $144.8 million and gross margin improved to 57%, up 460 basis points from 52% a year earlier. GAAP operating loss narrowed to $13.8 million, or negative 5% of sales, from $51.8 million, and GAAP net loss was $21.2 million, or $0.31 per share, compared with $52.4 million, or $0.78 per share. Adjusted EBITDA turned positive at $6.4 million, or 3% of sales.
For full-year 2026, Tandem reaffirmed sales guidance of approximately $1.065 billion to $1.085 billion, with U.S. sales of $730 million to $745 million and international sales of $335 million to $340 million. It expects gross margin of about 56% to 57% and adjusted EBITDA margin of about 5% to 6%, and now anticipates approximately $85 million of non-cash charges. Strategically, the company submitted a 510(k) for Tandem Mobi tubeless capability, gained new FDA clearances and CE Marks for Control-IQ+ in additional indications, expanded sensor compatibility with Dexcom G7 and Abbott FreeStyle Libre 3 Plus, and began the international commercial rollout of Tandem Mobi.